Clinical trials for cancer are research studies that test new ways to prevent, detect, or treat cancer in people. They are the final step between a promising laboratory discovery and a treatment your doctor can actually prescribe. Every standard cancer therapy available today, from chemotherapy drugs to immunotherapies, reached patients through this process. If you or someone you care about is considering a trial, understanding how they work can make the decision far less intimidating.
What Clinical Trials Actually Test
Most people assume clinical trials only test new drugs, but they cover a much wider range of questions. Treatment trials are the most common and evaluate new drugs, drug combinations, surgical techniques, or radiation approaches. Prevention trials test whether certain medications, vitamins, or lifestyle changes can reduce the risk of developing cancer in the first place. Screening trials compare methods for catching cancer earlier, such as a recent large-scale trial comparing standard 2-D digital mammography against newer 3-D tomosynthesis to see which better detects breast cancer.
Supportive care trials focus on improving quality of life for people already undergoing treatment. These might test better ways to manage nausea, fatigue, or pain. There are also precision medicine trials, which match treatments to specific genetic changes in a person’s tumor rather than just the tumor’s location in the body. One major example is ComboMATCH, a series of trials testing whether combinations of targeted therapies chosen based on the genetic makeup of each patient’s cancer can improve outcomes.
The Four Phases of a Cancer Trial
Clinical trials move through a series of phases, each answering a different question. A treatment doesn’t advance to the next phase unless it clears the one before it.
Phase 1 is about safety. A small group of around 15 to 30 people receives the treatment so researchers can identify side effects, determine whether people can tolerate it, and find the highest safe dose. These participants often have advanced cancers that haven’t responded to standard treatments.
Phase 2 expands the group to roughly 50 to 100 people and shifts the focus to effectiveness. Researchers look for signs the treatment is actually fighting the cancer, such as shrinking tumors or slowing their growth, while continuing to monitor side effects.
Phase 3 is the decisive comparison. Anywhere from 100 to several thousand participants are randomly assigned to receive either the new treatment or the current standard therapy. Random assignment is critical because it ensures any differences in outcomes reflect the treatment itself, not differences between the people in each group. If the new treatment proves better, these results support an application to the FDA for approval.
Phase 4 happens after a treatment is already approved and available to the public. These trials track long-term safety and effectiveness in larger, more diverse populations over months or years, catching rare side effects that smaller earlier trials might have missed.
Newer Trial Designs in Precision Medicine
Traditional trials test one drug for one type of cancer. But cancer biology doesn’t always follow those lines. Two newer designs, both operating under what’s called a “master protocol,” have changed how researchers approach this.
A basket trial tests a single targeted therapy across multiple types of cancer that share the same genetic mutation. For example, if lung, breast, and colon cancers all carry the same molecular change, patients with any of those cancers could enroll in one basket trial. The goal is to find treatments that work based on a tumor’s genetics regardless of where it started in the body.
An umbrella trial works in the opposite direction. It focuses on a single type of cancer, say advanced breast cancer, but divides patients into subgroups based on different genetic markers. Each subgroup then receives a different targeted therapy matched to their specific mutation. Running these as one coordinated trial is far more efficient than launching separate studies for every subgroup, which would require screening vastly more patients overall.
Who Can Join a Trial
Every trial has eligibility criteria that define who can and cannot participate. These exist to protect participants and to ensure the results are meaningful. Common factors include the type and stage of cancer, your age, general health and physical functioning, and what prior treatments you’ve had.
Exclusion criteria can be surprisingly specific. Many trials exclude people who have had a different cancer within the past three to five years, though exceptions are often made for non-melanoma skin cancers or other low-risk types. People with certain chronic infections, major psychiatric conditions, autoimmune diseases, or a history of substance abuse may also be excluded from some studies, depending on the treatment being tested and how it interacts with those conditions.
The National Cancer Institute offers a search tool at cancer.gov where you can look for trials by cancer type, your age, and your ZIP code to find studies enrolling near you. Your oncologist can also help identify trials that match your situation.
How You’re Protected as a Participant
Before you join any trial, you go through informed consent. This isn’t just signing a form. The research team is required to explain in plain language what the study involves, the known risks and possible side effects, any potential benefits, what alternative treatments exist outside the trial, how your personal information will be kept confidential, and what compensation or medical care is available if you’re harmed during the study. Participation is always voluntary, and you can leave a trial at any point for any reason.
Every trial must also be reviewed and approved by an Institutional Review Board, an independent committee that evaluates whether the study design adequately protects participants. The IRB has the authority to require changes to a study or reject it entirely before a single patient enrolls.
One common concern is whether you might receive a placebo instead of real treatment. In cancer trials, placebos are only used when no effective standard treatment exists for that specific situation. When a proven therapy is already available, it is considered unethical to withhold it. So participants in most cancer trials receive either the new treatment being studied or the best currently available therapy, not a sugar pill.
What It Costs to Participate
The costs of a clinical trial split into two categories. Research costs, which include the study drug itself, lab tests done purely for the trial, and extra imaging scans required by the study protocol, are typically covered by the trial’s sponsor. You generally won’t pay for those.
Patient care costs are the expenses you’d have regardless of the trial: doctor visits, hospital stays, standard cancer treatments, and managing side effects. These are usually billed to your health insurance the same way they would be for routine care. If you have Medicare, you may be reimbursed for certain costs related to participating in a trial that tests new ways to diagnose or treat cancer.
What catches some people off guard are the indirect costs. Travel, lodging, meals, parking, and childcare can add up, especially if the trial site isn’t close to home. Some studies offer financial assistance for these expenses, so it’s worth asking the research team directly what support is available before you commit.
Efforts to Make Trials More Inclusive
Historically, clinical trial participants have been disproportionately white, older, and male, which means the results may not fully reflect how a treatment works across all populations. The FDA has moved to address this. Under legislation passed as part of the FDA Omnibus Reform Act, sponsors of new drug and device trials are now required to submit diversity action plans outlining how they will improve enrollment of underrepresented populations. The FDA’s Oncology Center of Excellence is directly involved in implementing these requirements, and draft guidance issued in 2024 spells out the format, content, and evaluation process for these plans. The goal is to ensure that cancer treatments are tested in populations that actually reflect the people who will use them.